Bioengineering Strategies for Corneal Endothelial Cell Injection Therapy: Advances, Challenges, and Clinical Translation
Bioengineering · 26.10.2025 · 12 (11) · 1162
DOI: 10.3390/bioengineering12111162 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioengineering, online erschienen am 26.10.2025. Verfasst von Yura Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Republic of K…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Korean Fund for Regenerative Medicine (KFRM) grant funded by the Korea government ((the Ministry of Science and ICT, the Ministry of Health & Welfare), Korea government.
Abstract (Originalsprache)
Corneal endothelial dysfunction is a leading cause of vision impairment globally, traditionally managed through donor-dependent keratoplasty procedures. However, limitations in donor tissue availability, surgical complexity, and long-term graft survival have prompted the development of cell-based regenerative therapies. Among these, corneal endothelial cells (CECs) injection therapy has emerged as a minimally invasive alternative, offering the potential to restore endothelial function. This review provides a comprehensive analysis of recent advances in bioengineering strategies for CECs therapy, including cell sourcing from donor tissue, pluripotent stem cells, and transdifferentiated somatic cells; optimization of culture conditions and substrates; and delivery protocols that enhance cell adhesion and survival. We further examine clinical trial outcomes and propose future directions for clinical translation. The convergence of cell biology, biomaterials engineering, and translational medicine positions CECs injection therapy as a transformative solution to corneal blindness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea.
ORCID-Profile: Yura Choi
Förderung
- the Korean Fund for Regenerative Medicine (KFRM) grant funded by the Korea government ((the Ministry of Science and ICT, the Ministry of Health & Welfare)
- Korea government
Zitieren
APA
Choi, Y., Jung, M. Y., Han, E., & Park, C. Y. (2025). Bioengineering Strategies for Corneal Endothelial Cell Injection Therapy: Advances, Challenges, and Clinical Translation. Bioengineering, 12(11), 1162. https://doi.org/10.3390/bioengineering12111162
Vancouver
Choi Y, Jung MY, Han E, Park CY. Bioengineering Strategies for Corneal Endothelial Cell Injection Therapy: Advances, Challenges, and Clinical Translation. Bioengineering. 2025;12(11):1162. doi:10.3390/bioengineering12111162
BibTeX
@article{Choi2025,
author = {Choi, Yura and Jung, Mi-Young and Han, Eunsun and Park, Choul Yong},
title = {Bioengineering Strategies for Corneal Endothelial Cell Injection Therapy: Advances, Challenges, and Clinical Translation},
journal = {Bioengineering},
year = {2025},
volume = {12},
number = {11},
pages = {1162},
doi = {10.3390/bioengineering12111162}
}
EUVIMED